Liver disease induced coagulopathy - Revision history

Ostermayer: Prepared the page for translation

2026-01-04T23:17:49Z

Prepared the page for translation

← Older revision		Revision as of 23:17, 4 January 2026
Line 1:		Line 1:
			<languages/>
			<translate>

	==Background==		==Background==

	[[File:Liver vascular anatomy.png\|thumb\|Liver vascular anatomy.]]		[[File:Liver vascular anatomy.png\|thumb\|Liver vascular anatomy.]]


	==Clinical Features==		==Clinical Features==


	==Differential Diagnosis==		==Differential Diagnosis==

			</translate>
	{{Increased bleeding DDX}}		{{Increased bleeding DDX}}
			<translate>


	==Evaluation==		==Evaluation==

	*PT prolongation		*PT prolongation
	**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)		**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)
	*[[Thrombocytopenia]]		*[[Special:MyLanguage/Thrombocytopenia\|Thrombocytopenia]]
	**Portal hypertension → congestive hypersplenism → splenic sequestration		**Portal hypertension → congestive hypersplenism → splenic sequestration
	*Fibrinolysis increased		*Fibrinolysis increased
	**Due to decreased synthesis of alpha2 plasmin inhibitor		**Due to decreased synthesis of alpha2 plasmin inhibitor
	**Low fibrinogen level, mild elevation of FDP and D-dimer		**Low fibrinogen level, mild elevation of FDP and D-dimer


	==Management==		==Management==


	===Lab abnormalities only (with out significant bleeding)===		===Lab abnormalities only (with out significant bleeding)===

	*Observation		*Observation


	===Significant bleeding===		===Significant bleeding===
	*[[Vitamin K]] PO or IV
	*[[Desmopressin]]		*[[Special:MyLanguage/Vitamin K\|Vitamin K]] PO or IV
			*[[Special:MyLanguage/Desmopressin\|Desmopressin]]
	**Effective with minimal side effects		**Effective with minimal side effects
	**0.3mg/kg IV (preferred) or SC (max 20mg)		**0.3mg/kg IV (preferred) or SC (max 20mg)
	**Onset of action ~1hr, duration of action ~4-24hr		**Onset of action ~1hr, duration of action ~4-24hr
	*[[Cryoprecipitate]]		*[[Special:MyLanguage/Cryoprecipitate\|Cryoprecipitate]]
	**May be used to replace fibrinogen in patients with fibrinogen levels <100		**May be used to replace fibrinogen in patients with fibrinogen levels <100
	**1 bag per 10kg of body weight		**1 bag per 10kg of body weight
	*[[Platelets]]		*[[Special:MyLanguage/Platelets\|Platelets]]
	**Aim for >50K for moderate risk procedures; >100K for high risk procedures		**Aim for >50K for moderate risk procedures; >100K for high risk procedures
	*[[FFP]]		*[[Special:MyLanguage/FFP\|FFP]]
	**Use with caution; requires large volume of FFP to make a significant difference		**Use with caution; requires large volume of FFP to make a significant difference
	*[[PPI]]/[[famotidine]]/[[octreotide]] ([[variceal bleeding]])		*[[Special:MyLanguage/PPI\|PPI]]/[[Special:MyLanguage/famotidine\|famotidine]]/[[Special:MyLanguage/octreotide\|octreotide]] ([[Special:MyLanguage/variceal bleeding\|variceal bleeding]])

	[[Category:GI]]		[[Category:GI]]


	==Disposition==		==Disposition==


	==See Also==		==See Also==
	*[[Coagulopathy (Main)]]
			*[[Special:MyLanguage/Coagulopathy (Main)\|Coagulopathy (Main)]]


	==References==		==References==

	<references/>		<references/>
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]
			</translate>

Rossdonaldson1 at 23:03, 13 November 2024

2024-11-13T23:03:41Z

← Older revision		Revision as of 23:03, 13 November 2024
Line 1:		Line 1:
	==Background==		==Background==
	[[File:~~Sobo 1906 389~~.png\|thumb\|~~Inferior view of the liver with surface showing lobes and impressions~~.]]		[[File:Liver vascular anatomy.png\|thumb\|Liver vascular anatomy.]]

	==Clinical Features==		==Clinical Features==

Rossdonaldson1: /* Background */

2024-11-13T22:58:53Z

Background

← Older revision		Revision as of 22:58, 13 November 2024
Line 1:		Line 1:
	==Background==		==Background==
			[[File:Sobo 1906 389.png\|thumb\|Inferior view of the liver with surface showing lobes and impressions.]]

	==Clinical Features==		==Clinical Features==

ClaireLewis: /* Significant bleeding */

2019-09-29T18:48:10Z

Significant bleeding

← Older revision		Revision as of 18:48, 29 September 2019
Line 33:		Line 33:
	*[[FFP]]		*[[FFP]]
	**Use with caution; requires large volume of FFP to make a significant difference		**Use with caution; requires large volume of FFP to make a significant difference
	*[[PPI]]/[[famotidine]]/[[octreotide]] ([[variceal ~~bleed~~]])		*[[PPI]]/[[famotidine]]/[[octreotide]] ([[variceal bleeding]])

			[[Category:GI]]

	==Disposition==		==Disposition==

ClaireLewis: /* Significant bleeding */

2019-09-29T18:47:48Z

Significant bleeding

← Older revision		Revision as of 18:47, 29 September 2019
Line 29:		Line 29:
	**May be used to replace fibrinogen in patients with fibrinogen levels <100		**May be used to replace fibrinogen in patients with fibrinogen levels <100
	**1 bag per 10kg of body weight		**1 bag per 10kg of body weight
	*[[~~Platlets~~]]		*[[Platelets]]
	**Aim for >50K for moderate risk procedures; >100K for high risk procedures		**Aim for >50K for moderate risk procedures; >100K for high risk procedures
	*[[FFP]]		*[[FFP]]
	**Use with caution; requires large volume of FFP to make a significant difference		**Use with caution; requires large volume of FFP to make a significant difference
	*PPI/~~pepcid~~/octreotide (variceal bleed)		*[[PPI]]/[[famotidine]]/[[octreotide]] ([[variceal bleed]])

	==Disposition==		==Disposition==

ClaireLewis: /* Evaluation */

2019-09-29T18:46:50Z

Evaluation

← Older revision		Revision as of 18:46, 29 September 2019
Line 10:		Line 10:
	*PT prolongation		*PT prolongation
	**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)		**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)
	*Thrombocytopenia		*[[Thrombocytopenia]]
	**Portal hypertension → congestive hypersplenism → splenic sequestration		**Portal hypertension → congestive hypersplenism → splenic sequestration
	*Fibrinolysis increased		*Fibrinolysis increased

Mholtz: Text replacement - "==References== " to "==References== "

2017-07-24T01:12:50Z

Text replacement - "==References== " to "==References== <references/> "

← Older revision		Revision as of 01:12, 24 July 2017
Line 41:		Line 41:

	==References==		==References==
			<references/>
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Mholtz: Text replacement - "->" to "→"

2017-02-09T02:23:54Z

Text replacement - "->" to "→"

← Older revision		Revision as of 02:23, 9 February 2017
Line 11:		Line 11:
	**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)		**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)
	*Thrombocytopenia		*Thrombocytopenia
	**Portal hypertension -> congestive hypersplenism -> splenic sequestration		**Portal hypertension → congestive hypersplenism → splenic sequestration
	*Fibrinolysis increased		*Fibrinolysis increased
	**Due to decreased synthesis of alpha2 plasmin inhibitor		**Due to decreased synthesis of alpha2 plasmin inhibitor

Neil.m.young: Text replacement - "==Diagnosis==" to "==Evaluation=="

2016-07-22T20:01:30Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

← Older revision		Revision as of 20:01, 22 July 2016
Line 7:		Line 7:
	{{Increased bleeding DDX}}		{{Increased bleeding DDX}}

	==~~Diagnosis~~==		==Evaluation==
	*PT prolongation		*PT prolongation
	**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)		**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)

Neil.m.young: Text replacement - "3 mg" to "3mg"

2016-07-19T18:55:22Z

Text replacement - "3 mg" to "3mg"

← Older revision		Revision as of 18:55, 19 July 2016
Line 24:		Line 24:
	*[[Desmopressin]]		*[[Desmopressin]]
	**Effective with minimal side effects		**Effective with minimal side effects
	**0.~~3 mg~~/kg IV (preferred) or SC (max 20mg)		**0.3mg/kg IV (preferred) or SC (max 20mg)
	**Onset of action ~1hr, duration of action ~4-24hr		**Onset of action ~1hr, duration of action ~4-24hr
	*[[Cryoprecipitate]]		*[[Cryoprecipitate]]